RAD-140 vs LGD-4033: Development and Research Progress
RAD-140 (Testolone) and LGD-4033 (Ligandrol) are selective androgen receptor modulators (SARMs) developed to address muscle-wasting conditions. Despite this common goal, they differ significantly in their development stages and the availability of human research data.
RAD-140, created by Radius Health, remains in the preclinical research phase, emphasizing muscle wasting and exploring potential neuroprotective applications. In contrast, LGD-4033, developed by Ligand Pharmaceuticals, has progressed into early-stage human clinical trials, providing initial data on safety and tolerability in humans.
What Was RAD-140 Designed To Do?
RAD-140 was developed by Radius Health to focus on muscle wasting and potential neuroprotective effects by selectively interacting with androgen receptors in muscle and bone tissues. In practical terms, this means it aims to enhance muscle and bone health while minimizing unwanted impacts elsewhere in the body. RAD-140 remains in the preclinical phase, which includes laboratory and animal studies conducted before any human testing.
What Was LGD-4033 Designed To Do?
LGD-4033 was developed by Ligand Pharmaceuticals to address muscle wasting and osteoporosis-related conditions by selectively binding to androgen receptors in muscle and bone. This compound has advanced to early-stage human clinical trials, providing initial safety and tolerability data in humans, which is essential for further evaluation of its potential applications.
Key Differences
| Category | RAD-140 | LGD-4033 |
|---|---|---|
| Developer | Radius Health | Ligand Pharmaceuticals |
| Original Research Focus | Muscle wasting, neuroprotection | Muscle wasting, osteoporosis |
| Clinical Trial Progression | Preclinical studies | Early-stage human clinical trials |
| Availability of Human Data | No | Yes |
| Development Path | Selective targeting of muscle and bone | Selective interaction in muscle and bone |
What Actually Separates Them?
The primary difference lies in their stage of development. RAD-140 has not progressed to human trials, while LGD-4033 has provided early-phase clinical data, allowing for a more comprehensive evaluation regarding safety and tolerability in humans. This presence of human data makes it easier for researchers to assess clinical-stage compounds like LGD-4033 compared to preclinical ones like RAD-140.
Legal Considerations
For detailed legal information on SARMs, refer to our Global SARMs Legality Guide, SARMs Legal Status in the UK Guide, SARMs Legal Status in the United States Guide, and SARMs Legal Status in Canada Guide.
Research Disclaimer
Supplied for research purposes only. Not for human consumption. No usage advice provided.